Westport, Connecticut’s Portage Biotech presented new data Monday from a Phase I/II study of its invariant natural killer T cell (iNKT) agonist PORT-2, which is being tested for the treatment of melanoma and non-small cell lung cancer (NSCLC). 

Within the biopharmaceutical industry, there are companies of various sizes sharing a common goal: to create new treatment options. Successful companies must constantly evaluate their capabilities and know when to expand internally to fill a need

Sheila Frame is the President for the Americas at Amryt Pharma, founded on the belief that rare and ultra-rare diseases were an opportunity to support underserved patients differently than the big pharmaceutical companies could.

BlueSphere Bio, discusses how the company’s new platform technologies enable the rapid development of effective personalized T cell receptor (TCR) T cell therapies for the treatment of solid tumors with Pharma’s Almanac Editor in Chief David Alvaro, Ph.D.

Theseus Pharmaceuticals is developing what it calls “pan-variant” kinase inhibitors in the hopes of outsmarting tumors by anticipating the range of kinases that may drive their spread and growth as they change.

Regeneron has agreed to supply Elicio Therapeutics with the drug Libtayo for clinical trials of its candidate cancer vaccine, ELI-002.

Recce is developing new classes of anti-infectives that hold the potential to resolve multidrug-resistant in­fections safely and effectively.

MindMed tapped Greenway as CFO on Monday, as CEO Robert Barrow guides the company through what he called “an exciting point in our growth.” The New York-based psychedelics company was the second to ever go public on an American exchange, behind Compass Pathways. And this year, Barrow’s lining up “numerous near-term milestones ahead across our pipeline.”